Bloomberg News

Actavis Completes Purchase of Serbia’s Zdravlje for $9.2 Million

April 29, 2013

Actavis Inc. (ACT:US), the world’s fourth biggest maker of generic drugs, bought the entire equity of Serbia’s FHI Zdravlje AD as small shareholders sold their stock.

Actavis started the buyout on Nov. 2 to acquire 26.7 percent of the company it didn’t own and completed it at the cost of more than 7 million euros ($9.2 million), the company said in an e-mailed statement today.

Leskovac, Serbia-based Zdravlje was bought in 2002 for 3.5 million euros. Actavis said it invested more than 50 million euros in the plant, including the buyout.

To contact the reporter on this story: Misha Savic in Belgrade at msavic2@bloomberg.net

To contact the editor responsible for this story: James M. Gomez at jagomez@bloomberg.net


Burger King's Young Buns
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

Companies Mentioned

  • ACT
    (Actavis plc)
    • $211.54 USD
    • -4.01
    • -1.9%
Market data is delayed at least 15 minutes.
 
blog comments powered by Disqus